Búsqueda | Portal de Búsqueda de la BVS España

1.

Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis.

Pearlman, Brian L.

Dig Dis Sci; 69(5): 1551-1561, 2024 May.

Artículo en Inglés | MEDLINE | ID: mdl-38580885

2.

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.

Lok, Anna S; Sulkowski, Mark S; Kort, Jens J; Willner, Ira; Reddy, K Rajender; Shiffman, Mitchell L; Hassan, Mohamed A; Pearlman, Brian L; Hinestrosa, Federico; Jacobson, Ira M; Morelli, Giuseppe; Peter, Joy A; Vainorius, Monika; Michael, Larry C; Fried, Michael W; Wang, Gary P; Lu, Wenjing; Larsen, Lois; Nelson, David R.

Gastroenterology; 157(6): 1506-1517.e1, 2019 12.

Artículo en Inglés | MEDLINE | ID: mdl-31401140

3.

A Patient With Jaundice and Malaise.

Pearlman, Brian L.

JAMA; 327(24): 2448-2449, 2022 06 28.

Artículo en Inglés | MEDLINE | ID: mdl-35696255

4.

The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.

Pearlman, Brian L; Ehleben, Carole; Perrys, Michael.

Gastroenterology; 148(4): 762-70.e2; quiz e11-2, 2015 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-25557952

5.

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.

Pearlman, Brian L; Ehleben, Carole.

Hepatology; 59(1): 71-7, 2014 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-23873583

6.

How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?

Pearlman, Brian L.

Ann Intern Med; 171(11): 861-862, 2019 12 03.

Artículo en Inglés | MEDLINE | ID: mdl-31791051

7.

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.

Pearlman, Brian L; Traub, Nomi.

Clin Infect Dis; 52(7): 889-900, 2011 Apr 01.

Artículo en Inglés | MEDLINE | ID: mdl-21427396

8.

Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.

Pillai, Anjana A; Anania, Frank A; Pearlman, Brian L.

Am J Gastroenterol; 111(12): 1854-1856, 2016 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-27924099

9.

Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon.

Lara, James; Tavis, John E; Donlin, Maureen J; Lee, William M; Yuan, He-Jun; Pearlman, Brian L; Vaughan, Gilberto; Forbi, Joseph C; Xia, Guo-Liang; Khudyakov, Yury E.

In Silico Biol; 11(5-6): 213-24, 2011.

Artículo en Inglés | MEDLINE | ID: mdl-23202423

10.

The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.

Pearlman, Brian L.

Curr Gastroenterol Rep; 13(1): 78-86, 2011 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-21080244

11.

Reply: To PMID 23873583.

Pearlman, Brian L; Ehleben, Carole M.

Hepatology; 59(6): 2424, 2014 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-24122975

12.

You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.

Pearlman, Brian L; Lim, Tanna H.

Dig Dis Sci; 59(8): 1681-3, 2014 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-25002310

13.

Effect of interleukin-28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with pegylated interferon alpha-2a/ribavirin.

Pearlman, Brian L; Ehleben, Carole.

Hepatology; 55(5): 1645, 2012 May.

Artículo en Inglés | MEDLINE | ID: mdl-22212908

14.

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

Pearlman, Brian L; Ehleben, Carole; Saifee, Sophia.

Hepatology; 46(6): 1688-94, 2007 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-18046717

15.

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.

Pearlman, Brian L.

World J Gastroenterol; 14(23): 3621-7, 2008 Jun 21.

Artículo en Inglés | MEDLINE | ID: mdl-18595128

16.

Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.

Pearlman, Brian L; Hinds, Andrew E.

Aliment Pharmacol Ther; 48(9): 914-923, 2018 11.

Artículo en Inglés | MEDLINE | ID: mdl-30288771

17.

Hepatitis C virus infection in African Americans.

Pearlman, Brian L.

Clin Infect Dis; 42(1): 82-91, 2006 Jan 01.

Artículo en Inglés | MEDLINE | ID: mdl-16323096

18.

The IL-28B genotype predicts which slow-responding hepatitis C-infected patients will benefit from treatment extension.

Pearlman, Brian L; Ehleben, Carole.

Am J Gastroenterol; 106(7): 1370-1, 2011 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-21731027

19.

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.

Pearlman, Brian L; Ehleben, Carole.

Hepatology; 52(4): 1519-20; author reply 1520-1, 2010 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-20879035

20.

Increased Mitochondrial Genetic Diversity in Persons Infected With Hepatitis C Virus.

Campo, David S; Roh, Ha-Jung; Pearlman, Brian L; Fierer, Daniel S; Ramachandran, Sumathi; Vaughan, Gilberto; Hinds, Andrew; Dimitrova, Zoya; Skums, Pavel; Khudyakov, Yury.

Cell Mol Gastroenterol Hepatol; 2(5): 676-684, 2016 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-28174739

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis.

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.

A Patient With Jaundice and Malaise.

The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.

How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.

Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.

Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon.

The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.

Reply: To PMID 23873583.

You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.

Effect of interleukin-28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with pegylated interferon alpha-2a/ribavirin.

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.

Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.

Hepatitis C virus infection in African Americans.

The IL-28B genotype predicts which slow-responding hepatitis C-infected patients will benefit from treatment extension.

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.

Increased Mitochondrial Genetic Diversity in Persons Infected With Hepatitis C Virus.